Accumulating evidence has made everolimus approved for the treatment of metastatic ER positive, HER2 negative BC patients, because everolimus could effectively restrain the proliferation via inhibiting serine/ threonine kinase mTOR 2, 27. This evidence concerns the gene ERBB2 and breast cancer.